Acute spontaneous tumor lysis syndrome as the initial presentation of ALK-positive diffuse large B-cell lymphoma

Jennifer Chapman-Fredricks, Clifford Blieden, Jose D. Sandoval, Vinicius Ernani, Offiong Ikpatt

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

Anaplastic lymphoma kinase (ALK)-positive diffuse large B-cell lymphoma (DLBCL) is a recently described, uncommon form of DLBCL, which has been seen primarily in young men and which presents with advanced disease. The fact that ALK-positive DLBCL is an uncommon diagnosis is likely due to the combined effects of this being an uncommon disease coupled with the challenges in the pathologic identification of this neoplasm. Prompt and accurate identification of this tumor is becoming increasingly important, however, as we enter the era of therapeutic ALK inhibitors, which are currently undergoing study in several clinical trials. Here, we report a case of ALK-positive DLBCL in a 39-year-old male patient who presented with spontaneous tumor lysis syndrome. We review the clinical, morphologic, immunohistochemical, and molecular aspects of this case and of ALK-positive DLBCL in general, with the purpose of bringing to light the existence of this disease and its potential future therapy.

Original languageEnglish
Pages (from-to)317-321
Number of pages5
JournalApplied Immunohistochemistry and Molecular Morphology
Volume22
Issue number4
DOIs
StatePublished - Jan 1 2014

Fingerprint

Tumor Lysis Syndrome
Lymphoma, Large B-Cell, Diffuse
Neoplasms
anaplastic lymphoma kinase
Clinical Trials
Therapeutics

Keywords

  • ALK positive
  • Clathrin-ALK fusion protein
  • diffuse large B-cell lymphoma
  • malignant lymphoma
  • translocation (t2;5)
  • translocation t(2; 17)

ASJC Scopus subject areas

  • Pathology and Forensic Medicine
  • Medical Laboratory Technology
  • Histology

Cite this

Acute spontaneous tumor lysis syndrome as the initial presentation of ALK-positive diffuse large B-cell lymphoma. / Chapman-Fredricks, Jennifer; Blieden, Clifford; Sandoval, Jose D.; Ernani, Vinicius; Ikpatt, Offiong.

In: Applied Immunohistochemistry and Molecular Morphology, Vol. 22, No. 4, 01.01.2014, p. 317-321.

Research output: Contribution to journalArticle

@article{e7d4bf2711dd4ca78e03676a75af261a,
title = "Acute spontaneous tumor lysis syndrome as the initial presentation of ALK-positive diffuse large B-cell lymphoma",
abstract = "Anaplastic lymphoma kinase (ALK)-positive diffuse large B-cell lymphoma (DLBCL) is a recently described, uncommon form of DLBCL, which has been seen primarily in young men and which presents with advanced disease. The fact that ALK-positive DLBCL is an uncommon diagnosis is likely due to the combined effects of this being an uncommon disease coupled with the challenges in the pathologic identification of this neoplasm. Prompt and accurate identification of this tumor is becoming increasingly important, however, as we enter the era of therapeutic ALK inhibitors, which are currently undergoing study in several clinical trials. Here, we report a case of ALK-positive DLBCL in a 39-year-old male patient who presented with spontaneous tumor lysis syndrome. We review the clinical, morphologic, immunohistochemical, and molecular aspects of this case and of ALK-positive DLBCL in general, with the purpose of bringing to light the existence of this disease and its potential future therapy.",
keywords = "ALK positive, Clathrin-ALK fusion protein, diffuse large B-cell lymphoma, malignant lymphoma, translocation (t2;5), translocation t(2; 17)",
author = "Jennifer Chapman-Fredricks and Clifford Blieden and Sandoval, {Jose D.} and Vinicius Ernani and Offiong Ikpatt",
year = "2014",
month = "1",
day = "1",
doi = "10.1097/PAI.0b013e3182275c02",
language = "English",
volume = "22",
pages = "317--321",
journal = "Applied Immunohistochemistry and Molecular Morphology",
issn = "1541-2016",
publisher = "Lippincott Williams and Wilkins",
number = "4",

}

TY - JOUR

T1 - Acute spontaneous tumor lysis syndrome as the initial presentation of ALK-positive diffuse large B-cell lymphoma

AU - Chapman-Fredricks, Jennifer

AU - Blieden, Clifford

AU - Sandoval, Jose D.

AU - Ernani, Vinicius

AU - Ikpatt, Offiong

PY - 2014/1/1

Y1 - 2014/1/1

N2 - Anaplastic lymphoma kinase (ALK)-positive diffuse large B-cell lymphoma (DLBCL) is a recently described, uncommon form of DLBCL, which has been seen primarily in young men and which presents with advanced disease. The fact that ALK-positive DLBCL is an uncommon diagnosis is likely due to the combined effects of this being an uncommon disease coupled with the challenges in the pathologic identification of this neoplasm. Prompt and accurate identification of this tumor is becoming increasingly important, however, as we enter the era of therapeutic ALK inhibitors, which are currently undergoing study in several clinical trials. Here, we report a case of ALK-positive DLBCL in a 39-year-old male patient who presented with spontaneous tumor lysis syndrome. We review the clinical, morphologic, immunohistochemical, and molecular aspects of this case and of ALK-positive DLBCL in general, with the purpose of bringing to light the existence of this disease and its potential future therapy.

AB - Anaplastic lymphoma kinase (ALK)-positive diffuse large B-cell lymphoma (DLBCL) is a recently described, uncommon form of DLBCL, which has been seen primarily in young men and which presents with advanced disease. The fact that ALK-positive DLBCL is an uncommon diagnosis is likely due to the combined effects of this being an uncommon disease coupled with the challenges in the pathologic identification of this neoplasm. Prompt and accurate identification of this tumor is becoming increasingly important, however, as we enter the era of therapeutic ALK inhibitors, which are currently undergoing study in several clinical trials. Here, we report a case of ALK-positive DLBCL in a 39-year-old male patient who presented with spontaneous tumor lysis syndrome. We review the clinical, morphologic, immunohistochemical, and molecular aspects of this case and of ALK-positive DLBCL in general, with the purpose of bringing to light the existence of this disease and its potential future therapy.

KW - ALK positive

KW - Clathrin-ALK fusion protein

KW - diffuse large B-cell lymphoma

KW - malignant lymphoma

KW - translocation (t2;5)

KW - translocation t(2; 17)

UR - http://www.scopus.com/inward/record.url?scp=84898538243&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84898538243&partnerID=8YFLogxK

U2 - 10.1097/PAI.0b013e3182275c02

DO - 10.1097/PAI.0b013e3182275c02

M3 - Article

VL - 22

SP - 317

EP - 321

JO - Applied Immunohistochemistry and Molecular Morphology

JF - Applied Immunohistochemistry and Molecular Morphology

SN - 1541-2016

IS - 4

ER -